But a series of setbacks has dealt a blow to the field, including an announcement in late June by Intercept Pharmaceuticals that the Food and Drug Administration had said that the benefit of its proposed NASH treatment didnâ€™t outweigh the potential risks.The company said it would now embrace a new corporate strategy, details of which will be announced in September, that will focus on developing elafibranor in another disease, called primary biliary cholangitis, or PBC, and on its NASH diagnostic test.